CHAMPIONS ONCOLOGY, INC. CSBR
We are a technology-enabled research organization engaged in creating technology solutions to be utilized in drug discovery and development. Our research center operates in both regulatory and non-regulatory environments and consists of a comprehensive set of computational and experimental research platforms. Our pharmacology, biomarker, and data platforms are designed to facilitate drug discovery and development at lower costs and increased speeds.
At the core of our research platforms is our unique, proprietary bank of Patient Derived Xenograft (PDX) models. This preeminent bank of PDX models is deployed into advanced in vivo and ex vivo pharmacology platforms, providing an enhanced level of insight into therapeutic programs. We currently have approximately 1,500 PDX Models in our TumorBank that we believe reflect the characteristics of patients who enroll in clinical trials (late stage, pretreated and metastatic). This characteristic of our TumorBank is an important differentiator to other established PDX banks. We implant and expand these tumors in mice, which allows for future studies and additional characterization of the tumor. Additional analytical and pharmacology experimental platforms are also available to augment the information gained from studies performed.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $59.4M | $56.9M | $50.2M | $53.9M | $49.1M | $41.0M | $32.1M | $27.1M | $20.2M | $15.4M |
| Cost of revenue | $30.9M | $28.4M | $29.4M | $29.5M | $23.6M | $21.4M | $17.0M | — | — | — |
| Gross profit | $28.5M | $28.6M | $20.8M | $24.3M | $25.5M | $19.6M | $15.1M | — | — | — |
| R&D | $9.1M | $6.8M | $9.5M | $11.5M | $9.4M | $7.2M | $5.9M | $4.8M | $4.4M | $4.3M |
| SG&A | $11.2M | $9.3M | $11.1M | $10.2M | $9.1M | $6.5M | $6.6M | $4.7M | $4.1M | $5.0M |
| Total operating expenses | — | — | — | — | — | — | $33.9M | $26.8M | $21.6M | $22.2M |
| Operating income | -$1.1M | $4.6M | -$7.4M | -$5.3M | $607.0K | $366.0K | -$1.9M | $270.0K | -$1.4M | -$6.8M |
| Pre-tax income | -$929.0K | $4.6M | -$7.3M | -$5.3M | $583.0K | $437.0K | -$2.0M | $231.0K | -$1.4M | -$6.9M |
| Income tax | $246.0K | $75.0K | $32.0K | $68.0K | $35.0K | $75.0K | $130.0K | $103.0K | $33.0K | $19.0K |
| Net income | -$1.2K | $4.7K | -$7.3K | -$5.3M | $548.0K | $362.0K | -$2.1M | $128.0K | -$1.5M | -$6.9M |
| EPS, basic | -0.08 | 0.34 | -0.54 | -0.39 | 0.04 | 0.03 | -0.18 | 0.01 | -0.13 | — |
| EPS, diluted | -0.08 | 0.33 | -0.54 | -0.39 | 0.04 | 0.02 | -0.18 | 0.01 | -0.13 | -0.64 |
| Shares, diluted (wtd. avg.) | $13.8M | $14.3M | $13.5M | $13.5M | $14.2M | $14.6M | $11.8M | $14.1M | $11.0M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $4.9M | $9.8M | $2.6M | $10.1M | $9.0M | $4.7M | $8.3M | $3.2M | $1.0M | $3.4M |
| Receivables | $13.2M | $11.2M | $9.5M | $8.0M | $9.5M | $7.0M | $4.8M | $4.4M | $3.9M | $2.3M |
| Total current assets | $19.2M | $22.4M | $13.6M | $19.5M | $19.7M | $12.6M | $13.5M | $7.9M | $5.1M | $5.9M |
| Property, plant and equipment | — | — | — | — | — | $6.1M | $4.0M | $2.5M | $2.1M | $1.2M |
| Goodwill | $335.0K | $335.0K | $335.0K | $335.0K | $335.0K | $335.0K | $335.0K | $669.0K | $669.0K | $669.0K |
| Total assets | $27.0M | $32.3M | $26.1M | $34.3M | $35.4M | $27.6M | $20.8M | $11.3M | $8.1M | $8.0M |
| Accounts payable | $6.9M | $4.2M | $5.8M | $5.3M | $2.9M | $1.9M | $3.1M | $2.8M | $2.2M | $1.9M |
| Total current liabilities | $19.9M | $23.9M | $21.5M | $21.7M | $17.5M | $11.2M | $12.3M | $8.0M | $7.5M | $7.4M |
| Total liabilities | $22.9M | $28.6M | $28.0M | $29.7M | $26.3M | $20.2M | $15.7M | $9.0M | $8.1M | $7.6M |
| Retained earnings | -$81.1M | -$79.9M | -$84.6M | -$77.3M | -$72.0M | -$72.5M | -$72.9M | -$70.7M | -$70.8M | -$69.3M |
| Total equity | $3.9M | $3.8M | -$1.9M | $4.6M | $9.1M | $7.4M | $5.1M | $2.1M | $3.0K | $400.0K |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$4.5M | $7.4M | -$6.1M | $4.0M | $6.5M | -$1.7M | $2.9M | $1.9M | -$1.2M | -$2.8M |
| Depreciation and amortisation | $1.4M | $1.6M | $1.9M | $2.1M | $1.5M | $925.0K | $825.0K | $606.0K | $360.0K | $168.0K |
| Stock-based compensation | $1.2M | $654.0K | $1.1M | $864.0K | $912.0K | $598.0K | $600.0K | $636.0K | $1.0M | $2.7M |
| Capital expenditure | $564.0K | $389.0K | $836.0K | $2.9M | $2.4M | $3.3M | $2.2M | $834.0K | $1.2M | $766.0K |
| Investing cash flow | -$540.0K | -$389.0K | -$836.0K | -$2.9M | -$2.4M | -$3.2M | -$2.2M | -$834.0K | -$1.2M | -$766.0K |
| Financing cash flow | $99.0K | $170.0K | -$527.0K | $11.0K | $207.0K | $1.2M | $4.4M | $1.2M | $13.0K | $4.3M |
| Buybacks | — | $0 | $634.0K | $74.0K | $0 | — | — | — | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001628280-26-059373.
Others in SIC 2836
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AMGN | AMGEN INC | $236.38B | 30.7x | 10.0% |
| GILD | GILEAD SCIENCES, INC. | $187.23B | 22.3x | 2.4% |
| MRNA | Moderna, Inc. | $58.11B | — | -39.9% |
| RVMD | Revolution Medicines, Inc. | $45.01B | — | — |
| BIIB | BIOGEN INC. | $32.60B | 25.1x | 2.2% |
| SCNI | Scinai Immunotherapeutics Ltd. | $25.80B | — | 99.2% |
| NBIX | NEUROCRINE BIOSCIENCES INC | $15.82B | 33.3x | 21.4% |
| EXEL | EXELIXIS, INC. | $14.62B | 21.2x | 7.0% |